Eric Oksenhendler, MD; Philippe Bierling, MD; Françoise Ferchal, MD; Jean-Pierre Clauvel, MD; Maxime Seligmann, MD
Study Objective: To determine whether zidovudine is effective in increasing the platelet count in patients with thrombocytopenic purpura related to human immunodeficiency virus (HIV) infection.
Design: Nonrandomized controlled trial with two consecutive regimens.
Setting: Immunopathology and hematology clinics at two general hospitals.
Patients: Consecutive sample of 34 patients infected with HIV who had thrombocytopenic purpura (platelets < 50 X 109/L) without visceral bleeding. Twenty-nine patients completed the study; one patient was removed because of drug toxicity.
Interventions: Zidovudine for 12 weeks, 250 mg every 6 hours orally in 10 patients; and 500 mg every 8 hours orally in 24 patients.
Measurements and Main Results: Three of ten patients receiving 250 mg every 6 hours and 12 of 24 patients receiving 500 mg every 8 hours had a persistent increase in their platelet counts. In both groups the mean value of the platelet count increased significantly by week 12; from 28 X 109/L ± 12 (SD) to 57 X 109/L ± 36 in the first group and from 20 X 109/L ± 13 to 77 X 109/L ± 42 in the second group (P < 0.05 and P < 0.01, respectively).
Conclusions: Zidovudine is effective on platelet counts in some patients with HIV-related thrombocytopenia. These results suggest that HIV itself may play a direct or indirect role in the pathogenesis of this disorder.
Oksenhendler E, Bierling P, Ferchal F, Clauvel J, Seligmann M. Zidovudine for Thrombocytopenic Purpura Related to Human Immunodeficiency Virus (HIV) Infection. Ann Intern Med. ;110:365–368. doi: 10.7326/0003-4819-110-5-365
Download citation file:
Published: Ann Intern Med. 1989;110(5):365-368.
Coagulopathies, Hematology/Oncology, Infectious Disease, Platelet Disorders.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use